A Phase 3b Multicenter, Open-label Abiraterone Acetate Long-term Safety Study.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 01 Aug 2018
At a glance
- Drugs Abiraterone acetate (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Janssen Research & Development
- 03 May 2018 Planned End Date changed from 9 Apr 2018 to 9 Apr 2021.
- 03 May 2018 Planned primary completion date changed from 9 Apr 2018 to 9 Apr 2021.
- 16 Feb 2018 This trial has been completed in Spain, according to European Clinical Trials Database